Olipharma, a Contract Development and Manufacturing Organization (CDMO) specializing in small nucleic acid drugs and based in Suzhou, has reportedly secured an undisclosed amount of funding in a Pre-Series A+ financing round. The round saw participation from Tsing Song Capital, Addor Capital, and existing investor Matrix Partners. The proceeds are earmarked for the construction of manufacturing facilities, signaling the company’s expansion plans.
Company Background and Services
Founded in 2021, Olipharma has quickly established itself as a provider of comprehensive “one-stop” CDMO services in the small nucleic acid drug space. The company offers a range of services including drug design and screening, laboratory research and development, process and analysis development, CMC services, API production, and drug registration. This suite of services is underpinned by four core technology platforms: a nucleic acid solid phase synthesis platform, a chemical modification and coupling platform, a process development and analysis platform, and a CMC pharmaceutical research platform. These platforms enable Olipharma to deliver innovative solutions and support the development of nucleic acid drugs from concept to commercialization.-Fineline Info & Tech
